Table 1 Demographic and clinical characteristics of the patient population at baseline
|  | n = 40 patients |
|---|---|
Age (years), mean (SD) | 54.6 (14) |
Females, n (%) | 32 (80) |
Disease duration (months), median (IQR) | 38 (19–115) |
DAS28, mean (SD) | 4.87 (0.84) |
SJC28, median (IQR) | 4 (1.5–5.5) |
TJC28, median (IQR) | 8 (4–12.5) |
VAS PtGA (mm), median (IQR) | 65 (50–80) |
HAQ-DI, median (IQR) | 1.125 (0.75–1.5) |
ESR (mm/1 h), median (IQR) | 22 (18–36.5) |
CRP (mg/dl), median (IQR) | 0.9 (0.3–2.75) |
12-joint GS index, median (IQR) | 13 (8.5–18.5) |
12-joint PD index, median (IQR) | 2 (0–5.5) |
IgM RF positive, n (%) | 26 (65) |
IgM RF titer (U/ml), median (IQR)a | 85 (42.5–274) |
IgG ACPA positive, n (%) | 27 (67.5) |
IgG ACPA titer (U/ml), median (IQR)a | 66 (27.2–287.5) |
Erosive disease, n (%)b | 23/32 (71.9) |
Current treatment with MTX, n (%) | 36 (90) |
Receiving corticosteroids, n (%) | 31 (77.5) |
Receiving NSAIDs, n (%) | 9 (22.5) |
Number of previous csDMARDs, median (range) | 1 (0–3) |